Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients

• Published in: Journal of hepatology Vol. 70; no. 5; pp. 866 - 873
• Main Authors: Doyle, Adam, Gorgen, Andre, Muaddi, Hala, Aravinthan, Aloysious D., Issachar, Assaf, Mironov, Oleg, Zhang, Wei, Kachura, John, Beecroft, Robert, Cleary, Sean P., Ghanekar, Anand, Greig, Paul D., McGilvray, Ian D., Selzner, Markus, Cattral, Mark S., Grant, David R., Lilly, Leslie B., Selzner, Nazia, Renner, Eberhard L., Sherman, Morris, Sapisochin, Gonzalo
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2019; Elsevier Science Ltd
• Subjects: Hepatocellular carcinoma; Hepatoma; Liver cancer; Liver transplant; Liver transplantation; Locoregional therapy; Metastases; Patients; Radiofrequency ablation; Risk factors; Surgery; Survival; Transplants & implants; Tumors; α-Fetoprotein; Liver transplant; Radiofrequency ablation; Liver cancer; Hepatoma; Locoregional therapy
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/j.jhep.2018.12.027

[Display omitted] •Most patients with single HCC ≤3 cm treated by RFA will eventually develop recurrent HCC distant to the ablation site.•Many patients treated with HCC will recur beyond the Milan criteria despite close post-RFA surveillance.•Patients with tumors >2 cm and higher serum alpha-fetoprotein are at greater risk of recurrence beyond Milan criteria. Radiofrequency ablation (RFA) is an effective treatment for single hepatocellular carcinoma (HCC) ≤3 cm. Disease recurrence is common, and in some patients will occur outside transplant criteria. We aimed to assess the incidence and risk factors for recurrence beyond Milan criteria in potentially transplantable patients treated with RFA as first-line therapy. We performed a retrospective cohort study of potentially transplantable patients with new diagnoses of unifocal HCC ≤3 cm that underwent RFA as first-line therapy between 2000-2015. We defined potentially transplantable patients as those aged <70 years without any comorbidities that would preclude transplant surgery. Incidence of recurrence beyond Milan criteria was compared across 2 groups according to HCC diameter at the time of ablation: (HCC ≤2 cm vs. HCC >2 cm). Competing risks Cox regression was used to identify predictors of recurrence beyond Milan criteria. We included 301 patients (167 HCC ≤2 cm and 134 HCC >2 cm). Recurrence beyond Milan criteria occurred in 36 (21.6%) and 47 (35.1%) patients in the HCC ≤2 cm and the HCC >2 cm groups, respectively (p = 0.01). The 1-, 3- and 5-year actuarial survival rates after RFA were 98.2%, 86.2% and 79.0% in the HCC ≤2 cm group vs. 93.3%, 77.6% and 70.9% in the HCC >2 cm group (p = 0.01). Tumor size >2 cm (hazard ratio 1.94; 95%CI 1.25–3.02) and alpha-fetoprotein levels at the time of ablation (100–1,000 ng/ml: hazard ratio 2.05; 95%CI 1.10–3.83) were found to be predictors of post-RFA recurrence outside Milan criteria. RFA for single HCC ≤3 cm provides excellent short- to medium-term survival. However, we identified patients at higher risk of recurrence beyond Milan criteria. For these patients, liver transplantation should be considered immediately after the first HCC recurrence following RFA. Radiofrequency ablation and liver transplantation are treatment options for early stages of hepatocellular carcinoma (HCC). After ablation some patients will experience recurrence or metastatic spread of the initial tumor or may develop new tumors within the liver. Despite close follow-up, these recurrences can progress rapidly and exceed transplant criteria, preventing the patient from receiving a transplant. We identified that patients with HCC >2 cm and higher serum alpha-fetoprotein are at greater risk of recurrence beyond the transplant criteria. These data suggest that liver transplantation should be considered immediately after the first HCC recurrence for these patients.